RxDoctor Payments Data

Nathan Boggs, APRN

Family · Huntington, WVNPI 1205393741

Payments from drug & device makers

$6,455in general payments, 2019–2025

Across 177 payments — averaging $36.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Medtronic$1K
  • Johnson & Johnson$697
  • Sumitomo Pharma America, Inc.$521
  • Convatec Inc.$434
  • Endo USA, Inc.$347
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$1,81528%
  • Food & beverage$4,42168%
  • Education$2193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,455 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$35,994
Medicare patients
312
Services billed
631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron306$252,598
GemtesaVibegron189$150,249
Trimethoprim207$11,807
Tamsulosin Hcl505$6,246
Estradiol80$5,372
Solifenacin Succinate158$4,761
NitrofurantoinNitrofurantoin Macrocrystal117$2,848
Tobramycin Sulfate199$1,771
Oxybutynin Chloride ErOxybutynin Chloride90$1,731
Finasteride136$1,707
Alfuzosin Hcl ErAlfuzosin Hcl47$993
Gentamicin Sulfate19$969
Sodium Chloride0.9 % Sodium Chloride63$834
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$822
Testosterone Cypionate16$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$262$252,598306 claims
Sumitomo Pharma America, Inc.Gemtesa$521$150,249189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →